Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Researchers develop new approach to fighting chemo-resistant small cell lung cancer

Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate.

21 Sep 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023

Researchers receive £2.66M to test new immunotherapeutic strategy for non-small cell lung cancer

University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the most deadly cancers.

13 Sep 2023

Study reveals key reproductive factors that may increase lung cancer risk in women

A study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer revealed that key reproductive factors such as early menopause, shortened reproductive span, and early age at first birth are associated with elevated risks of lung cancer in women.

12 Sep 2023

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.

11 Sep 2023

Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancer

The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.

11 Sep 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

From AMGEN 1 Sep 2023

The Clinical Importance of Circulating Tumor DNA

Cancer remains a leading killer among medical causes of death worldwide.

31 Aug 2023

New discoveries about a type of immune cells could pave the way for improved immunotherapies

Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.

30 Aug 2023

Non-traditional gene fusions in luminal breast cancer: A new target for therapy

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"

21 Aug 2023

Epigenetic manipulation may improve breast cancer treatment responses

Researchers explore the possibility of increasing TROP2 ADC activity by enhancing the expression of TROP2 on cancer cells.

15 Aug 2023

Pembrolizumab combination therapies effective for advanced NSCLC, study shows

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

12 Jul 2023

Immunotherapy significantly improves overall survival for advanced NSCLC patients

A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.

6 Jul 2023

Pioneering methodology reveals novel biomarkers for non-small cell lung cancer

Researchers of the University of Barcelona and the Institute of Bioengineering of Catalonia have identified new biomarkers for non-small cell lung cancer, the most common lung cancer.

20 Jun 2023

Assessing the role of Docetaxel post-chemoimmunotherapy for patients with NSCLC

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)."

8 Jun 2023

Targeted therapy for non-small cell lung cancer provides benefit to patients after surgery

A clinical trial led by Yale Cancer Center shows that the drug osimertinib, a targeted therapy for non-small cell lung cancer, improved rates of survival and reduced risk of recurrence in patients after surgery.

7 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

Stopping treatment at two years does not seem to compromise overall survival in patients with advanced lung cancer

Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease.

4 Jun 2023

NCCN collaborates with K Hospital and Vietnam Cancer Association to improve standards for cancer care

he National Comprehensive Cancer Network-;a not-for-profit alliance of leading cancer centers in the United States-;today announced the signing of a Memo of Understanding (MOU) with Vietnam National Cancer Hospital ("K Hospital") and the Vietnam Cancer Association to work together to improve standards for cancer care throughout the country.

1 Jun 2023